Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMA1-C1/Alhydrogel malaria vaccine in Malian children
NCT00341250Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AMA1-C1/Alhydrogel in malaria, sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2006; status: completed.
02
Drugs
AMA1-C1/Alhydrogel
03
Conditions
malaria
Beyond the preview
Go deeper on NCT00341250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00341250.